Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.45 |
| ▸ | DRD3 | P35462 | 7/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634328 | 0.89 | DRD3 (0.46) | MCHR1KCNH2DRD3DRD2HTR2C | |
| SCHEMBL4793677 | 0.88 | MCHR1 (0.52) | MCHR1KCNH2DRD3DRD2HTR2C | |
| SCHEMBL4725409 | 0.88 | MCHR1 (0.52) | MCHR1KCNH2DRD3DRD2HTR2C | |
| SCHEMBL4795358 | 0.86 | DRD3 (0.45) | MCHR1KCNH2DRD3DRD2HTR2C | |
| SCHEMBL5935171 | 0.85 | DRD3 (0.42) | MCHR1KCNH2DRD3DRD2HTR2C | |
| SCHEMBL4794868 | 0.84 | DRD3 (0.41) | MCHR1KCNH2DRD3DRD2HTR2C | |
| SCHEMBL4779647 | 0.84 | DRD3 (0.42) | MCHR1KCNH2DRD3DRD2HTR2C | |
| SCHEMBL4781349 | 0.84 | DRD3 (0.46) | MCHR1KCNH2DRD3DRD2HTR2C | |
| SCHEMBL4792233 | 0.84 | DRD3 (0.44) | MCHR1KCNH2DRD3DRD2HTR2C | |
| SCHEMBL4793754 | 0.84 | DRD3 (0.46) | MCHR1KCNH2DRD3DRD2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 4050/4885DRD3 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.